MedTrace Logo

Diagnostic Utility of [18F]-FDG-PET/CT and [124I]-PET/CT for Detection of Recurrence in Differentiated Thyroid Carcinoma

NCT01374659 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2011-06-16

No results posted yet for this study

Summary

Several studies have indicated that \[124I\]-PET/CT or \[18F\]-FDG-PET/CT may be useful to locate recurrent differentiated thyroid carcinoma lesions in patients with elevated thyroglobulin levels but who do not show pathological lesions when conventional imaging modalities are used. Thus, the investigators evaluated the effectiveness of PET/CT using both \[124I\] and \[18F\]-FDG in such patients.

Conditions

Sponsors & Collaborators

  • Korean Association of Endocrine Surgeons

    lead NETWORK

Principal Investigators

  • Jandee Lee, MD · Korean Association of Endocrine Surgeons

Eligibility

Min Age
15 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2011-06-30
Completion
2012-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01374659 on ClinicalTrials.gov